Clinical and regulatory changes must be made to asthma management to ensure it reflects current scientific understanding of the disease, and the needs of patients, say asthma experts. These conclusions form part of the ‘Brussels Declaration’, defining changes that need to be made in order to improve outcomes for asthma patients, developed by leading asthma experts, together with EU policymakers, regulators and patient groups attending the ‘Summit for Change in Asthma Management’, which took place at the EU Parliament on 18th and 19th October 2006.
Key areas for action identified during the Summit, hosted by Liberal Democrat MEP, Liz Lynne (UK) and co-chaired by leading asthma expert Professor Stephen Holgate of the University of Southampton (UK) include: a rapid need to update national and international clinical guidelines on the treatment of asthma, including the EMEA Guidance Note on Asthma; ensure all patients and professionals fully understand the current thinking behind asthma management; inclusion of wider measures of asthma control in studies and practice, which take into account patient quality of life. In addition, the EU Parliament was encouraged with making asthma, its research and its management a political priority through mechanisms such as the European Parliament Initiative Report.Professor Holgate defines the Summit and the resulting Declaration as a great step forward for asthma management and patients: “This meeting has been extremely valuable as it has allowed health care professionals, scientists and patient groups to work directly with regulators and policymakers to establish where and how improvements need to be made in order for asthma patients to receive optimum treatment. However, our work does not end here; it is vital that all of the actions agreed upon are also acted upon to ensure asthma patients benefit fully.”
During the Summit various clinicians presented information which showed asthma to be a systemic inflammatory disease which affects more than just the lungs and thus the need to control inflammation is essential. However, current guidelines and practice are based on a historical view of diagnosis and treatment of asthma which only measure airflow in the lungs and so may not truly capture whether the inflammation is under control or whether other parts of the body are affected by the same type of inflammation. Furthermore, data also shows that patients respond differently to treatments and one option may not suit all. Therefore treatment should be individualised to meet the needs of the patient. Unfortunately, current methods of assessing therapies that influence the wider aspects of allergic inflammation are not reflected in guidelines which currently are restrictive in their recommendations and limit the choice of treatments available for clinicians to choose from.
The Cost of Asthma
It is estimated that over 30 million people in Europe have asthma and the number is rising.1 In addition, deaths from asthma have reached 180,000 annually 2 and the economic cost of asthma in Europe is thought to be in the region of €17 billion per year with an annual productivity loss estimated at €9.8bn.3 The economic and social costs of asthma are largely due to uncontrolled disease, and are likely to rise as its prevalence, complexity and severity increases4 and therefore improvement in disease control would substantially reduce costs.
Rosie Allan | alfa
Finnish research group discovers a new immune system regulator
23.02.2018 | University of Turku
Minimising risks of transplants
22.02.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg
A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.
In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...
A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.
By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...
Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...
For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.
In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...
Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale
Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...
15.02.2018 | Event News
13.02.2018 | Event News
12.02.2018 | Event News
23.02.2018 | Physics and Astronomy
23.02.2018 | Health and Medicine
23.02.2018 | Physics and Astronomy